Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Covalon achieves profit leap in Q3 2026 thanks to rising margins
Covalon reported Q3 fiscal 2026 revenue of CAD 10.0m (+20% y/y), net income of CAD 2.8m (prior year CAD 65,000) and adjusted EBITDA of CAD 3.0m. Gross margin rose to 67.2% from 46.5% a year earlier, driving a strong margin expansion and substantially higher gross profit. Management attributes the improvement to stronger U.S. demand, particularly for contamination-protection products (growth ~51%), and to operational scale effects, viewing the quarter as part of a multi-year strategy. The stock traded only slightly lower and remains near its 52-week high; the company remains a small-cap with further growth potential. » More on de.investing.com
Covalon Technologies reports robust revenue and margin growth in Q2 2026
Covalon Technologies posted revenue of CAD 8.7 million in the second quarter of 2026 (+14.5% year‑over‑year) and diluted EPS of CAD 0.04, which doubled versus the year‑ago quarter. Gross margin rose to 61.5% (previously 54.5%) and adjusted EBITDA climbed to CAD 1.3 million (+127%). Operating expenses increased 15% due to regulatory and testing costs, which could weigh on future profitability. For fiscal 2027 the company expects negative EPS development but continues to focus on growth in U.S. and international markets as well as investments in automation and efficiency. » More on de.investing.com
Covalon Technologies reports steady revenue and special dividend for Q4 2025
Covalon Technologies recorded revenue of $8.7m in Q4 2025 (unchanged year‑on‑year) and its seventh consecutive profitable quarter. For the fiscal year, revenue rose 5% to $32.8m; gross margin was 53% (56% adjusted). The company announced its first special dividend of CAD 0.15 per share, holds CAD 17m in liquidity and plans to drive growth through US market expansion, sales and partnerships. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 6.2m | 18.66% |
| Gross profit | 4.03m | 66.22% |
| Net profit | 1.73m | 4,207.45% |
| EBITDA | 1.84m | 2,049.13% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €78.27m |
Number of shares | 27.62m |
52-week high/low | €3.26 - €1.04 |
Dividend yield | 3.27% |
Dividends TTM | €0.0926 |
Beta | 0.03 |
P/E ratio | 28.16 |
PEG ratio | 0.30 |
P/B ratio | 3.88 |
P/S ratio | 3.56 |
Company profile
Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.
| Name | COVALON TECHNOLOGIES NEW Aktie |
| CEO | Brent Ashton |
| Headquarters | Mississauga,
on Canada |
| Website | |
| IPO | 18/04/2007 |
| Employees | 105 |